Pain-related hyperactivity in the amygdala leads to deactivation of the medial prefrontal cortex (mPFC) and decision-making deficits. The mechanisms of pain-related inhibition of the mPFC
Introduction
The medial prefrontal cortex (mPFC) plays an important role in cognitive functions such as decision making, avoidance of risky choices and goal-directed behaviors in animals and humans (Bechara et al. 1999; Kouneiher et al. 2009; Pais-Vieira et al. 2007; Stalnaker et al. 2007; Vertes 2006) . Pain has been associated with functional and structural abnormalities in prefrontal cortical areas (Apkarian et al. 2004b; Metz et al. 2009 ) and can impair emotion-based decision-making in humans (Apkarian et al. 2004c ) and animals (Ji et al. 2010; Pais-Vieira et al. 2009 ). A recent study from our laboratory showed that hyperactivity in the amygdala, an emotional brain center closely interconnected with the mPFC, leads to the deactivation of the mPFC (Ji et al. 2010) , but the underlying mechanism remains to be determined.
Here we tested the hypothesis that group I metabotropic glutamate receptors (mGluRs) activate a GABAergic mechanism to inhibit the activity of mPFC pyramidal cells. Glutamatergic afferents from extra-cortical areas such as the amygdala have been shown to target inhibitory GABAergic interneurons that synapse on pyramidal cells in layer V of the mPFC (Bacon et al. 1996; Gabbott et al. 2006; Kita and Kitai 1990) . Group I mGluR1 and mGluR5 subtypes modulate excitatory and inhibitory synaptic transmission in various brain areas and have emerged as therapeutic targets for neuropsychiatric disorders associated with cortical dysfunction (Lesage and Steckler 2010; Niswender and Conn 2010; Olive 2010; Pinheiro and Mulle 2008) . mGluR1 can activate glutamate-driven synaptic inhibition in the cerebellum (Karakossian and Otis 2004) . A recent study from our laboratory showed that mGluR1 also activates feedforward inhibition of mPFC pyramidal cells (Sun and Neugebauer 2011) .
Both mGluR1 and mGluR5 subtypes are expressed in the prefrontal cortex (Cauli et al. 2000; Muly et al. 2003) . Activation of group I mGluRs in the mPFC increased GABA release (Segovia and Mora 2005) whereas mGluR1 mediated enhanced glutamate release (Melendez et al. 2005 ). An mGluR1/5 agonist (DHPG) increased excitatory transmission (Marek and Zhang 2008) but also inhibitory transmission onto prefrontal pyramidal cells (Chu and Hablitz 1998) .
Systemic application of a positive allosteric modulator for mGluR5 increased activity of mPFC pyramidal cells in normal animals but reversed hyperexcitability of pyramidal cells in a schizophrenia model (Homayoun and Moghaddam 2010) . In our recent study DHPG-activated synaptic inhibition of mPFC pyramidal cells in slices from normal animals was blocked by an antagonist for mGluR1 but not mGluR5 (Sun and Neugebauer 2011).
The diversity of effects suggests that mGluR subtypes are well positioned to fine-tune activity of mPFC pyramidal cells but their role in different conditions and models remains to be determined. The present study was designed to examine the contribution of mGluR1 and mGluR5 to enhanced inhibition of mPFC neurons in a rat model of arthritic pain, using electrophysiological single-unit recordings and pharmacology in vivo.
Methods
Adult male Sprague Dawley rats (250-350 g) were housed in a temperature controlled room and maintained on a 12 h day/night cycle. Water and food were available without restriction. All 
Animal preparation and anesthesia
Experimental details have been described in detail in our previous studies (Ji et al. 2010; Ji and Neugebauer 2009 ). The animal was anesthetized with pentobarbital sodium (50 mg · kg -1 , administered intraperitoneally). A cannula was inserted into the trachea for artificial respiration and to measure end-tidal CO2 levels. A catheter was placed in the jugular vein for continuous administration of anesthetic (see below) and for fluid support (3-4 ml · kg -1 · h -1 lactated Ringer solution, administered intravenously, i.v.). The animal was kept under anesthesia throughout the experiment. Constant levels of anesthesia were maintained with pentobarbital (15 mg/kg per h, i.v.). They were paralyzed with pancuronium (0.3 mg/h, i.v.) and artificially ventilated (3-3.5 ml;
55-65 strokes/min). End-tidal CO 2 levels (kept at 4.0 ± 0.2 %), heart rate and electrocardiogram (ECG) pattern were continuously monitored. Core body temperature was maintained at 37 °C by means of a homeothermic blanket system. These measures ensured a constant internal state of body functions. The animal was mounted in a stereotaxic frame (David Kopf Instr.) and a small unilateral craniotomy was performed at the sutura fronto-parietalis level. The dura mater was opened and reflected; the pia mater was removed over the recording and drug administration sites to allow smooth insertion of the recording electrode and microdialysis probe.
Electrophysiological recording and identification of mPFC neurons
As described in detail previously (Ji et al. 2010) , extracellular recordings were made from single neurons in the prelimbic part of the mPFC with glass insulated carbon filament electrodes (4 -6 MΩ) using the following stereotaxic coordinates (Paxinos and Watson 1998): 3.0-3.2 mm anterior to bregma; 0.5 -1.0 mm lateral to midline; depth 3.0-4.6 mm. Using an electronically remote-controlled micro-stepping positioner attached to the stereotaxic frame (David Kopf Instr.) the electrode was lowered vertically into the mPFC. Recording electrode and ground electrode were connected with a pre-amplifier (WPI) to a differential amplifier (Warner Instr.) . The recorded signals were amplified, band-pass filtered (300 Hz to 3 kHz), and displayed on analog and digital storage oscilloscopes. Signals were also fed into a window discriminator (WPI), whose output was processed by an interface (CED 1401 Plus) connected to a Pentium 4 PC. established or discussed in these references we selected neurons with peak-to-valley spike width greater than 500 µs and a baseline discharge rate lower than 10 Hz (Ji et al. 2010 ).
Spikes were detected and recorded based on the waveform signal that crossed a trigger level and matched a pre-set shape or template that was created for the individual neuron at the beginning of the recording period. Spike size and configuration were continuously monitored on the storage oscilloscopes and with the use of Spike2 software. Only those neurons were included in this study whose spike configuration remained constant (matching the template) and could be clearly discriminated from activity in the background throughout the experiment, indicating that the activity of one and the same one neuron was measured.
Experimental protocol
In each animal, background activity and evoked responses of only one neuron were recorded as described in detail in our previous studies (Ji et al. 2010; Ji and Neugebauer 2007; 2009 applied to the knee and other deep tissue are considered innocuous because they do not evoke hind limb withdrawal reflexes in awake rats and are not felt to be painful when tested on the experimenters. Pressure stimuli >1500 g/30 mm 2 are noxious because they evoke hind limb withdrawal reflexes and vocalizations in awake rats and are distinctly painful when applied to the experimenters (Han et al. 2005; Neugebauer et al. 2007; Neugebauer and Li 2002) . For the analysis of net evoked activity, background activity in the 15 s time period preceding the 15 s stimulus was subtracted from the total activity during stimulation.
To determine changes in the arthritis pain model, one and the same neuron was recorded continuously before and after arthritis induction, allowing paired analysis. For the pharmacological analysis of receptor function, one neuron was recorded before and during drug administration into the mPFC. Before and during drug applications, intervals between test stimuli were 5-10 min; this protocol was the same under normal conditions (no arthritis) and in the arthritis pain state. Sufficiently long control periods were included in each experiment to establish the baseline activity before arthritis induction and/or drug application. Number of stimulations was kept at a minimum in order to avoid any "sensitization" that might be produced by repeated stimulation. The rationale for testing evoked responses was to link the mPFC neurons to pain processing and pain mechanisms. Throughout the experiment we carefully monitored several physiological parameters (body temperature, heart rate, ECG, endtidal CO 2 levels) to ensure a stable recording situation.
Arthritis pain model
Arthritis was induced as described in detail previously (Neugebauer et al. 2007) . A kaolin suspension (4%, 100 ml) was slowly injected into the joint cavity through the patellar ligament with the use of a syringe and needle (1 ml, 25 gauge, 5/8 in). After repetitive flexions and extensions of the knee for 15 min, a carrageenan solution (2%, 100 ml) was injected into the knee joint cavity, and the leg was flexed and extended for another 5 min. This treatment paradigm reliably leads to a localized inflammation confined to one knee joint within 1-3 h, persists for weeks and is significantly associated with pain behaviors (Neugebauer et al. 2007 ).
Drugs and drug application
The following selective compounds were used. 5-Aminomethyl-3-hydroxyisoxazole (muscimol, CMA/Microdialysis; membrane diameter: 250 μm, membrane length: 1 mm) was lowered vertically into the mPFC and positioned stereotaxically within the prelimbic cortex, using the following coordinates: 3.2 mm anterior to bregma; 0.8 mm lateral to midline; depth 4.3 mm (Ji et al. 2010) . The distance between microdialysis probe and recording electrode was 0.5-1.0 mm.
In some experiments, a microdialysis probe was inserted into the anterior cingulate cortex as a placement control, using the following stereotaxic coordinates: 2.7 mm anterior to bregma; 0.8 mm lateral to midline; depth of tip 3.0 mm. Using PE-50 tubing, the microdialysis probe was connected to an infusion pump (Harvard) and perfused with artificial cerebrospinal fluid (ACSF) containing (in mM): NaCl 125.0, KCl 2.6, NaH2PO4 2.5, CaCl2 1.3, MgCl2 0.9, NaHCO3 21.0, and glucose 3.5; oxygenated and equilibrated to pH = 7.4. Before each drug application, ACSF was pumped through the fiber for at least 1 h to establish equilibrium in the tissue.
Drugs were dissolved in ACSF on the day of the experiment at a concentration 100
times that predicted to be needed based on our previous microdialysis and in vitro studies ( 
Histology
At the end of each experiment the recording site in the mPFC was marked by injecting direct current (250 µA for 3 min) through the carbon filament recording electrode. The brain was removed and submerged in 10% formalin and potassium ferrocyanide. Tissues were stored in 20% sucrose before they were frozen sectioned at 50 µm. Sections were mounted on gelcoated slides, stained with hematoxylin and eosin (H&E) and cover-slipped. Lesion/recording sites were verified histologically and plotted on standard diagrams (adapted from Paxinos and Watson 1998).
Data analysis and statistics
Extracellularly recorded single-unit action potentials were analyzed off-line from peristimulus rate histograms using Spike2 software (CED, version 4). Responses to mechanical stimuli were measured and expressed as spikes per second (Hz). Background activity was subtracted from the total activity during the stimulus to calculate net evoked activity. 
Results
Extracellular single-unit recordings were made from 69 neurons in the prelimbic region of the medial prefrontal cortex (mPFC) in 69 rats ( Fig. 1 ). Neurons included in this study responded to noxious mechanical stimulation of peripheral tissues, including the knee joint (see Methods).
Receptive fields of prelimbic mPFC neurons were bilateral and symmetrical in the hindlimbs and tail (n = 69) as determined with brief innocuous and noxious mechanical test stimuli (see Methods). The majority of neurons (n = 41) had additional symmetrical receptive fields in the forepaws and trunk. Action potential duration (582.64 ± 59.08 µs, peak-to-valley) and firing rate (4.31±1.95 spikes/s) were consistent with pyramidal cells rather than fast-spiking interneurons (see Methods and Ji et al. 2010 ).
Pain-related deactivation of mPFC neurons involves a GABAergic mechanism
To determine arthritis pain-related changes, background activity and responses to innocuous (500 g/30 mm 2 ) and noxious (2000 g/30 mm 2 ) stimuli were measured repeatedly in the same mPFC neuron (n = 10) before and for 5-6 h after induction of an arthritis pain state (Fig. 2 ).
Interspike interval (ISI) analysis of background activity showed a decrease after arthritis induction ( Fig. 2C ). Cumulative ISI distribution shifted towards higher values (P < 0.05, Kolmogorov-Smirnov test) and mean frequency decreased significantly (n = 10 neurons, P < 0.01, paired t-test; Fig. 2D ). Responses to innocuous and noxious compression of the knee also decreased after arthritis induction significantly (n = 10 neurons, P < 0.01 and 0.001, paired t-test;
Fig. 2G,H).
The results confirm the pain-related decrease in background and evoked activity of mPFC neurons described in our previous study (Ji et al. 2010) . Decreased activity in the pain state was observed in all prelimbic neurons tested (n = 10). Therefore, drugs in the pharmacological studies were tested not only in neurons that were monitored continuously before and after arthritis induction but also in neurons that were only identified in the arthritis pain state.
Administration of a GABAA receptor antagonist (bicuculline, 1 mM, concentration in microdialysis probe, 15 min) into the prelimbic mPFC reversed the decrease in background and evoked activity of mPFC neurons in the arthritis pain state (Fig. 3) . The facilitatory effects of bicuculline in the pain model (5-6 h postinduction) were significant in the sample of mPFC neurons (n = 6, P < 0.01, ANOVA with Bonferroni post-tests; Fig. 4A ; for individual data see Fig.   4B ). Bicuculline (1 mM, n = 6 neurons) increased background activity and responses to innocuous and noxious stimuli to 78±10, 74±7, and 87±8 % of pre-arthritis values, respectively.
Off-site injection into the ACC (n = 5 neurons) as a control for drug diffusion did not change background activity but had some inhibitory effect on evoked activity of prelimbic neurons, possibly indicating an inverse relationship between anterior cingulate and prelimbic cortices. A GABAB receptor antagonist (CGP55845, 500 µM, n = 5 neurons) had no effect. The data suggest that GABAA receptors in the prelimbic mPFC mediate deactivation of pyramidal cells in the arthritis pain model.
Pain-related deactivation of mPFC neurons involves mGluR1 but not mGluR5
Under normal conditions (Fig. 4C ), exogenous activation of mGluR1/5 with a selective agonist (DHPG, 100 µM, n = 6 neurons) inhibited background and evoked activity (P < 0.01, ANOVA
with Bonferroni post-tests). The inhibitory effect was blocked by bicuculline (1 mM, n = 5 neurons), suggesting the involvement of GABAA receptors in group I mGluR-activated inhibition of mPFC neurons. Individual examples are shown in Figure 5A and 5B. Bicuculline (1 mM, n = 5 neurons) reversed the inhibitory effect of a GABAA receptor agonist (muscimol, 100 µM, n = 5 neurons; Fig. 5D ). Muscimol inhibited background and evoked activity of mPFC neurons in a concentration-dependent fashion (n = 7-8 neurons per concentration; Fig. 5C ). The similarity of the effect of bicuculline on the inhibition induced by DHPG and by muscimol suggests the involvement of GABAA Receptors.
Bicuculline alone had no effect on evoked activity but increased background activity (n = 5 neurons, P < 0.05, ANOVA with Bonferroni post-tests, Fig. 4C ; for individual data see Fig. 4D ), which would be consistent with a GABAergic tone in the mPFC. In the arthritis pain state (Fig.   4A ), DHPG (100 µM) alone had no effect on the suppressed activity of mPFC neurons (n = 5 neurons). DHPG also had no effect when the activity was restored to pre-arthritis levels by blocking GABAA receptors with bicuculline (n = 5 neurons). We interpret our data to suggest that the inhibitory GABAA receptor-mediated effect of DHPG seen under normal conditions is occluded in the arthritis pain model by the endogenous activation of GABAergic inhibition.
Since DHPG inhibited mPFC activity through a GABAergic mechanism under normal conditions (Figs. 4C and 5) and GABAA receptors mediate pain-related inhibition of mPFC neurons in the arthritis model (Fig. 4A) , we hypothesized that mGluR1 or mGluR5 may be activated endogenously in the pain state to depress mPFC activity. Administration of a selective antagonist for mGluR1 (LY367385, 1 mM; Fig. 6 ) 5 h postinduction of arthritis partially reversed the depressed responses of an mPFC neuron. In contrast, a selective mGluR5 antagonist (MPEP, 100 µM) had no effect (Fig. 7) . The data for the sample of neurons are summarized in for individual data see Fig. 8B ). In those neurons that were recorded before and after arthritis induction LY367385 (1 mM, n = 3 neurons) increased background activity and responses to innocuous and noxious stimuli to 73±15, 68±13, and 65±13 % of pre-arthritis values, respectively. The values for MPEP (1 mM, n = 3 neurons) were 34±3, 45±6 and 32±7 % of prearthritis levels. LY367385 (1 mM, n = 5 neurons) and MPEP (100 µM, n = 4 neurons) had no effect under normal conditions (n = 4 neurons each; Fig. 8C ; for individual data see Fig. 8D ).
The results suggest that arthritis pain increases the GABAergic tone in the mPFC through a mechanism that involves mGluR1 and GABAA receptor activation.
Discussion
This study tested the hypothesis that the endogenous activation of group I mGluRs contributes to enhanced GABAergic inhibition of mPFC neurons in an arthritis pain model described in our previous study (Ji et al. 2010) . Key findings are as follows. Our data show a pain-related decrease in background and evoked activity of mPFC neurons that process nociceptive information. Selective antagonists for GABAA receptors (bicuculline) and mGluR1 (LY367385), but not mGluR5 (MPEP), reverse the enhanced inhibition of mPFC neurons in the arthritis pain state. The results suggest that endogenous activation of GABAA receptors and mGluR1
contributes to pain-related decreased mPFC activity. Our data further show that exogenous activation of mGluR1/5 with a selective agonist (DHPG) inhibits mPFC neurons under normal conditions and this effect is blocked with bicuculline, suggesting that mGluRs can regulate mPFC output (action potential firing) through a GABAergic mechanism. In the arthritis pain state, when mGluR1 and GABAA receptors are endogenously activated to inhibit mPFC activity, exogenous activation of group I mGluRs with DHPG has no effect. DHPG also has no effect when activity is restored to pre-arthritis levels with bicuculline. The results are consistent with the concept that pain-related mPFC deactivation is mediated by the endogenous activation of 
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show similar decision-making deficits that result in disadvantageous choices because of their 12 inability to switch strategies.
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The mechanisms of pain-related mPFC dysfunction remain to be determined. The 
53
The mechanism by which feedforward inhibition in the mPFC is activated in pain remains 54 to be determined. Group I mGluR1 and mGluR5 subtypes can modulate excitatory and The data of the present study suggest that mGluR1 rather than mGluR5 mediates the increased inhibition of mPFC pyramidal cells in a model of arthritis pain. A selective antagonist for mGluR1 (LY367385), but not mGluR5 (MPEP), partially reversed the inhibition of background and evoked activity of mPFC cells. A selective antagonist for GABAA (bicuculline), but not GABAB (CGP55845), receptors largely restored pre-arthritis control levels of mPFC activity, emphasizing the GABAergic nature of pain-related mPFC deactivation. The fact that blockade of mGluR1 only partially restored normal activity may suggest that other receptors or mechanisms contribute to the activation of feedforward inhibition or that inhibitory interneurons have undergone plasticity that is not easily reversed by blocking their mGluR1-mediated activation. Non-GABAergic (for example peptidergic) inhibitory mechanisms could also be involved in mPFC deactivation. Linking mGluR1 directly to GABAergic inhibition in the pain model is difficult to accomplish with the in vivo approach of the present study, because our hypothesis implies that activation of mGluR1 or GABAA receptors would produce similar results.
We chose two strategies to address this issue. Under normal conditions, DHPG produced inhibition which was reversed by bicuculline. This finding is consistent with our recent patchclamp study that showed mGluR1 activates feedforward inhibition to decrease output function of mPFC pyramidal cells (Sun and Neugebauer 2011). In arthritis, DHPG alone or coapplication of DHPG with bicuculline did not produce inhibition of activity. These data also argue against a direct effect of mGluR1 on pyramidal cells but suggest the involvement of a GABAergic mechanism. The definitive link between mGluR1 and feedforward inhibition of mPFC pyramidal cells through activation of GABAergic interneurons would require analysis at the synaptic levels using a brain slice preparation. On the other hand, the whole animal preparation in this study allowed the analysis of specific inputs such as those related to noxious stimuli.
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Methodological considerations and caveats
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The conclusions of this electrophysiological study rely on the results of pharmacological 
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The site of drug action and spread of drugs also need to be considered. In this study, off-
98
site injections into the ACC as a control for drug diffusion did not change background activity but 99 had some inhibitory effect on evoked activity (particularly by noxious stimuli) of prelimbic 100 neurons. Opposite effects of drug injections into prelimbic cortex and ACC argue for site-specific drug actions and may indicate an inverse relationship between these cortical areas. In fact, pain-related synaptic plasticity was found in the ACC that correlated positively with pain behavior (Li et al. 2010; Wu et al. 2005 ) whereas activity in the prelimbic cortex decreased in 104 this and our previous study (Ji et al. 2010) , resulting in cognitive deficits.
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The deactivation of mPFC neurons after arthritis induction is unlikely the result of non- 
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The pain-related activity change is the consequence of receptor-dependent activation of 113 inhibitory cortical mechanisms.
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Significance Dysfunction of the prefrontal cortex (PFC) is associated with cognitive decision-making deficits 115 (Bechara et al. 1998; 1999) (mGluR1/5 agonist, 100 µM, n = 5) or CGP55845 (GABAB receptor antagonist, 500 µM) into the prelimbic mPFC had no effect (n = 5 neurons). Administration of bicuculline (Bicuc., GABAA receptor antagonist, 1 mM) into the prelimbic mPFC (n = 6), but not anterior cingulate cortex (ACC, n = 5), increased background and evoked activity. In the presence of bicuculline, DHPG (100 µM, n = 5) had no effect. B, Raw data show the facilitatory effect of bicuculline (1 mM 
